964 results on '"Larrey, Dominique"'
Search Results
2. CDK4/6 inhibitor-induced liver injury: Clinical phenotypes and role of corticosteroid treatment
3. Clinical pattern of checkpoint inhibitor-induced liver injury in a multicentre cohort
4. SAT-306 Time to use the right classification to predict the severity of checkpoint inhibitor-induced liver injury
5. SAT-331 Anticancer drugs are the first cause of drug-induced liver injury in the REFHEPS network
6. Cannabis use as a factor of lower corpulence in hepatitis C-infected patients: results from the ANRS CO22 Hepather cohort
7. Drug‐induced liver injury related to gene therapy: A new challenge to be managed.
8. Early hepatocellular carcinoma detection using magnetic resonance imaging is cost-effective in high-risk patients with cirrhosis
9. RE: Praluent (Alirocumab)-Induced Renal Injury
10. CDK4/6 inhibitors-induced liver injury: Clinical phenotypes and role of the corticosteroid treatment
11. Large-scale screening of lipase acid deficiency in at risk population
12. Including Ratio of Platelets to Liver Stiffness Improves Accuracy of Screening for Esophageal Varices That Require Treatment
13. Long-term safety and efficacy of lomitapide in patients with homozygous familial hypercholesterolemia: Five-year data from the Lomitapide Observational Worldwide Evaluation Registry (LOWER)
14. Chemotherapy-associated steatohepatitis
15. Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials
16. irLI or Not irLI: That is the Question
17. HLA associations with infliximab-induced liver injury
18. Hepatitis C virus infection impacts work productivity and fatigue: An epidemiologic real-life study
19. EASL Clinical Practice Guidelines: Drug-induced liver injury
20. A Missense Variant in PTPN22 is a Risk Factor for Drug-induced Liver Injury
21. Validation of Baveno VI Criteria for Screening and Surveillance of Esophageal Varices in Patients With Compensated Cirrhosis and a Sustained Response to Antiviral Therapy
22. Retreatment With Sofosbuvir Plus Grazoprevir/Elbasvir Plus Ribavirin of Patients With Hepatitis C Virus Genotype 1 or 4 Who Previously Failed an NS5A- or NS3-Containing Regimen : The ANRS HC34 REVENGE Study
23. The long-term, real-world effectiveness and safety of lomitapide in homozygous familial hypercholesterolaemia (HoFH): Nine-year data from the lomitapide observational worldwide evaluation registry (lower)
24. irLI or not irLI: That is the question
25. Drug-Induced Liver Injury and COVID-19 Infection: The Rules Remain the Same
26. Incidence of Hepatocellular Carcinoma After Direct Antiviral Therapy for HCV in Patients With Cirrhosis Included in Surveillance Programs
27. Dronedarone, amiodarone and other antiarrhythmic drugs, and acute liver injuries: a case-referent study
28. Compliance With Hepatocellular Carcinoma Surveillance Guidelines Associated With Increased Lead-Time Adjusted Survival of Patients With Compensated Viral Cirrhosis: A Multi-Center Cohort Study
29. Recent Advances in Hepatotoxicity of Non Steroidal Anti-inflammatory Drugs
30. CDK 4/6 inhibitors induced liver injury: 7 cases from REFHEPS registry
31. Liver Biopsy in Chronic Liver Diseases: Is There a Favorable Benefit: Risk Balance?
32. LOWER, a registry of lomitapide-treated patients with homozygous familial hypercholesterolemia: Rationale and design
33. Safety and efficacy of the combination simeprevir-sofosbuvir in HCV genotype 1- and 4-mono-infected patients from the French ANRS CO22 hepather cohort
34. Hepatotoxicity of Drugs Used in Multiple Sclerosis, Diagnostic Challenge, and the Role of HLA Genotype Susceptibility
35. Early virological assessment during telaprevir- or boceprevir-based triple therapy in hepatitis C cirrhotic patients who failed a previous interferon based regimen – The ANRS CO20-CUPIC study
36. ABO blood group does not influence Child‐Pugh A cirrhosis outcome: An observational study from CIRRAL and ANRS CO12 CIRVIR cohorts
37. Lack of Efficacy of an Inhibitor of PDE4 in Phase 1 and 2 Trials of Patients With Nonalcoholic Steatohepatitis
38. Liver Stiffness by Transient Elastography to Detect Porto‐Sinusoidal Vascular Liver Disease With Portal Hypertension
39. Drug-induced Hepatotoxicity
40. Effectiveness and Safety of Tenofovir Disoproxil Fumarate in Chronic Hepatitis B: A 3-Year, Prospective, Real-World Study in France
41. Predictive factors of virological response at one year in patients with chronic HBV/HDV co-infected treated with Bulevirtide
42. Treatment with Bulevirtide in patients with chronic HBV/HDV co-infection. Safety and efficacy at month 18 in real-world settings
43. Impact of direct-acting antiviral treatment for hepatitis C on cardiovascular diseases and extrahepatic cancers
44. The Lomitapide Observational Worldwide Evaluation Registry (LOWER) - Nine-year Effectiveness and Safety Data in HoFH
45. Relative Risks from Case-Population Data
46. Immunotherapy and Gene Therapy: New Challenges in the Diagnosis and Management of Drug-Induced Liver Injury.
47. Daclatasvir plus sofosbuvir, with or without ribavirin, for hepatitis C virus genotype 3 in a French early access programme
48. Bacterial infection in compensated viral cirrhosis impairs 5-year survival (ANRS CO12 CirVir prospective cohort)
49. Population pharmacokinetics of micafungin in ICU patients with sepsis and mechanical ventilation
50. Impact of direct‐acting antiviral treatment for hepatitis C on cardiovascular diseases and extrahepatic cancers.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.